Windtree Therapeutics Inc (WINT)

11:44 AM

Windtree Therapeutics CEO to retire with company's future in doubt - The Business Journals

11:44 AM

Nov 16, 2024

Leadership Transition at Windtree Therapeutics: Fraser Retires, Latkin Takes Helm - MyChesCo

Nov 16, 2024

Nov 15, 2024

Windtree Therapeutics Announces CEO Transition and Appointment of New Chief Executive Officer - Defense World

Nov 15, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Windtree Therapeuti - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Windtree Therapeutics Appoints Jed Latkin as New CEO - TipRanks

Nov 14, 2024

Nov 14, 2024

Windtree Therapeutics announces CEO Fraser to retire, Latkin to succeed - TipRanks

Nov 14, 2024

Nov 14, 2024

Windtree Therapeutics announces CEO transition - Investing.com

Nov 14, 2024

Nov 14, 2024

Windtree Announces Leadership Transition Plan With Industry Veterans - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Windtree Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2024 - Marketscreener.com

Nov 14, 2024

Nov 13, 2024

WINT Stock Hits 52-Week Low at $0.53 Amid Steep Decline - Investing.com

Nov 13, 2024

Nov 13, 2024

WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands - Yahoo Finance

Nov 13, 2024

Nov 06, 2024

Windtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure Treatment - MSN

Nov 06, 2024

Nov 06, 2024

WINT stock touches 52-week low at $0.62 amid sharp annual decline - Investing.com

Nov 06, 2024

Nov 04, 2024

Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock - MSN

Nov 04, 2024

Nov 04, 2024

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong - GlobeNewswire

Nov 04, 2024

Oct 30, 2024

Windtree Therapeutics Initiates SEISMiC C Study of - GlobeNewswire

Oct 30, 2024

Oct 30, 2024

Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 - The Manila Times

Oct 30, 2024

Oct 29, 2024

Windtree Therapeutics Secures Global Patent Filings for Istaroxime - MSN

Oct 29, 2024

Oct 28, 2024

Windtree Therapeutics announces $27.24 million equity sale option - Investing.com India

Oct 28, 2024

Oct 28, 2024

Windtree Therapeutics announces $27.24 million equity sale option By Investing.com - Investing.com UK

Oct 28, 2024

Oct 26, 2024

Windtree Therapeutics Prepares to Highlight Istaroxime Progress at ThinkEquity Conference - MSN

Oct 26, 2024

Oct 24, 2024

Windtree Therapeutics completes national phase filings for istaroxime - Yahoo Finance

Oct 24, 2024

Oct 23, 2024

Windtree Therapeutics advances global patent filings for shock therapy - Investing.com

Oct 23, 2024

Oct 23, 2024

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewswire

Oct 23, 2024

Oct 22, 2024

Windtree To Present at the ThinkEquity Conference on October 30th - GlobeNewswire

Oct 22, 2024

Oct 20, 2024

Reviewing Windtree Therapeutics (NASDAQ:WINT) and INmune Bio (NASDAQ:INMB) - Defense World

Oct 20, 2024

Oct 19, 2024

Windtree Therapeutics Secures Patent for Heart Failure Treatment in Japan - MSN

Oct 19, 2024

Oct 17, 2024

Windtree Therapeutics secures Japan patent for heart drug - Investing.com

Oct 17, 2024

Oct 17, 2024

Windtree Therapeutics secures Japan patent for heart drug By Investing.com - Investing.com Australia

Oct 17, 2024

Oct 17, 2024

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - The Manila Times

Oct 17, 2024

Oct 17, 2024

A significant driver of top-line growth: Windtree Therapeutics Inc (WINT) - SETE News

Oct 17, 2024

Oct 15, 2024

Windtree Therapeutics Inc (WINT) Stock: The Story of a 52-Week Stock Range - The InvestChronicle

Oct 15, 2024

Oct 14, 2024

Recent Insider Activity Suggests Potential Gains for Windtree Therapeutics Inc (WINT) - Knox Daily

Oct 14, 2024

Oct 14, 2024

Was Windtree Therapeutics Inc (WINT)’s session last reading good? - US Post News

Oct 14, 2024

Oct 14, 2024

WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones - Research Tree

Oct 14, 2024

Oct 13, 2024

Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MSN

Oct 13, 2024

Oct 10, 2024

Ladenburg Thalmann slashes price target on Windtree Therapeutics Inc [WINT] – find out why. - The DBT News

Oct 10, 2024

Oct 10, 2024

Windtree Therapeutics CEO buys $4.9k in company stock - Investing.com India

Oct 10, 2024

Oct 09, 2024

Windtree Therapeutics advances Phase 2b cardiogenic shock study By Investing.com - Investing.com Australia

Oct 09, 2024

Oct 09, 2024

Windtree Therapeutics CEO buys $4.9k in company stock By Investing.com - Investing.com Australia

Oct 09, 2024

Oct 09, 2024

WINT’s Stock Journey: What Investors Need to Know About Windtree Therapeutics Inc’s Performance - The InvestChronicle

Oct 09, 2024

Oct 09, 2024

Windtree Therapeutics advances Phase 2b cardiogenic shock study - Investing.com India

Oct 09, 2024

Oct 09, 2024

Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - The Manila Times

Oct 09, 2024